In RA, ACNs reduce the release of inflammatory factors by inhibiting the activation of NF-кB, MAPK, and JAK/STAT3 signaling pathways and restore the balance of the immune system by inhibiting oxidative stress. This evidence concerns the gene STAT3 and rheumatoid arthritis.